Chemistry:BIIB033
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | Anti-LINGO-1 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
BIIB033 (also known as Anti-LINGO-1) is a monoclonal antibody targeting LINGO1. As of 2015 it was being developed by Biogen as a treatment for diseases such as multiple sclerosis and optic neuritis.[1][2][3]
See also
References
- ↑ "Biogen MS Drug Results Are 'Mildly Encouraging' In Eye Disease Test". https://www.forbes.com/sites/matthewherper/2015/04/14/biogen-ms-drug-results-are-mildly-encouraging-in-eye-disease-test/.
- ↑ Clinical trial number NCT01864148 for "Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex" at ClinicalTrials.gov
- ↑ "Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033". Neurology 1 (2): e18. August 2014. doi:10.1212/NXI.0000000000000018. PMID 25340070.
 |  |
